this is a positive surprise to me that IHL is running a Phase 2A trial. Previously they said they’re trials were going to be phase 1 only. Phase 2 is obviously more significant.
as a comparison, BOT announced the results of a phase 1B trial on the 19th and it’s really pushed the share price forward. The ‘patient enrolment’ for their study was only 15 patients but IHL is recruiting 40 patients.
good to see that they’ve confirmed the commencement of the other trials for next quarter.
personally to me this is now one of the best medcan stocks on the ASX but with one of the smallest market capitalisations.
Ted
IHL Price at posting:
3.6¢ Sentiment: Buy Disclosure: Held
